Comprehensive Cancer Centers of Nevada (CCCN) - Central Valley

Las Vegas, Nevada 89169

2 studies enrolling now · 10 studies all time

What they study most

Adult Solid Tumor, Advanced Solid Tumors, Bladder Cancer, Breast Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Castrate-Resistant Prostate Cancer, Cholangiocarcinoma, Colorectal Cancer, Head and Neck Cancer, Head and Neck Neoplasms, Lymphoma, Large-Cell, Anaplastic

Studies at this site

• Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors — Recruiting now
• A Clinical Study of YL205 in Patients With Advanced Solid Tumors — Recruiting now
• A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors — Completed
• Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) — Running, not enrolling
• A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) — Stopped early
• A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment — Stopped early
• Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer — Completed
• Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid Tumors — Stopped early
• Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor — Completed
• A Study to Investigate the Bioequivalence or Relative Bioavailability of Three New Idasanutlin Tablet Variants Following Oral Administration in Participants With Solid Tumors — Completed